Experience of determination of antitumor drugs concentrations as a method of providing the safety of pharmacotherapy
| Autor: | Gennadii G. Rodionov, Rodion A Oseshnyuk, Ekaterina A. Kolobova, Inna E. Ushal, Ekaterina V. Svetkina, Igor I Shantyr, Petr D. Shabanov |
|---|---|
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Reviews on Clinical Pharmacology and Drug Therapy. 16:64-70 |
| ISSN: | 2542-1875 1683-4100 |
| DOI: | 10.17816/rcf16164-70 |
| Popis: | Background. The undesirable side effects in the process of pharmacotherapy are forced to look for ways to prevent them. The most effective means for this is to carry out individual therapeutic drug monitoring. This is especially true for patients who undergo chemotherapy. A narrow therapeutic range of antineoplastic agent concentrations requires an individual approach to the management of each patient. The purpose of this study is to justify the need for therapeutic drug monitoring to provide the safety of antitumor drugs. Methods. Methods for the quantitative determination of the active metabolite of fludarabine, imatinib and gefitinib in human blood plasma have been developed and validated. A study of pharmacokinetics of antitumor drugs: fludarabine - 36 patients, gefitinib - 24 healthy volunteers, imatinib - 24 healthy volunteers. Results and Discussion. The work shows the magnitude of interindividual differences of the pharmacokinetics of various antitumor drugs. High interindividual variability of pharmacokinetic parameters was revealed both in patients and in healthy volunteers. Conclusion. Experience of the Research Laboratory of Toxicology and Drug Monitoring, The Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia on the application of therapeutic drug monitoring showed its relevance and effectiveness for patients undergoing chemotherapy. (For citation: Rodionov GG, Shantyr II, Ushal IE, et al. Experience of determination of antitumor drugs concentrations as a method of providing the safety of pharmacotherapy. Reviews on Clinical Pharmacology and Drug Therapy. 2018;16(1):64-70. doi: 10.17816/RCF16164-70). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|